Max Chat
Calendrier des promotions Anebulo Pharmaceuticals, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.Paramètres de base
IPO date
2021-05-07
ISIN
US0345691036
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 18.96 | 1 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -104.19 | 0 |
| ROE | -113.8 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 0 | 10 |
| Debt/Ratio | 0 | 10 |
| Debt/Equity | 0.0683 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 123.62 | 10 |
| Rentabilité EPS, % | -75.49 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 1.39 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 1.16 $ | 0 $ | 0 $ | 19.83 % | 0 % | 0 % |
| common.calendar.number_days.30d | 1.12 $ | 1.08 $ | 1.39 $ | 24.11 % | 0 % | 0 % |
| common.calendar.number_days.90d | 0.9752 $ | 0.9447 $ | 1.39 $ | 42.53 % | 0 % | 0 % |
| common.calendar.number_days.180d | 1.57 $ | 0.9447 $ | 2.04 $ | -11.46 % | 0 % | 0 % |
| common.calendar.number_days.1y | 1.83 $ | 0.9447 $ | 3.08 $ | -23.89 % | 0 % | 0 % |
| common.calendar.number_days.3y | 3.35 $ | 0.9447 $ | 4.6 $ | -58.51 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0.9447 $ | 0.9447 $ | 8.95 $ | 147.14 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.9447 $ | 0.9447 $ | 8.95 $ | 147.14 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 1.6 $ | 0.9447 $ | 2.04 $ | -13.13 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman | 11k | 1972 (53 année) |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer | 425.15k | 1959 (66 années) |
| Mr. Richard Anthony Cunningham | CEO & Director | N/A | 1971 (54 année) |
| Mr. Daniel V. George | Principal Accounting Officer, Acting CFO & Secretary | N/A | 1970 (55 années) |
Informations sur l'entreprise
Adresse: United States, Lakeway. TX, 1017 Ranch Road 620 South - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.anebulo.com
Site web: https://www.anebulo.com
